Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health IT’s Potential Patient Safety Risks Draws House Panel’s Letter To HHS

This article was originally published in The Pink Sheet Daily

Executive Summary

Healthcare and Technology subcommittee chairman prods HHS to describe how it will monitor health information technology to reduce risks to patient safety; the Institute of Medicine recently called for more such government oversight.

You may also be interested in...

EHRs Become A Stronger Research Tool Under Proposed Stage 2 Meaningful Use Rule

Use of electronic health records to report data to disease registries, for both cancer and non-cancer conditions, becomes an optional objective for providers to demonstrate “meaningful use” of EHRs under CMS’ proposed stage 2 requirements. An objective to identify patients for potential research opportunities also carries over to the stage 2 proposal.

IOM Calls For More Government Oversight Of Health IT

The Institute of Medicine offers a series of recommendations to HHS to enhance the agency’s oversight of health IT, and calls on the private sector to be more engaged in sharing safety data with both the public and private sectors.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts